Found: 46
Select item for more details and to access through your institution.
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01117-4
- By:
- Publication type:
- Article
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00955-y
- By:
- Publication type:
- Article
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Biological Insights into Myeloma and Other B Cell Malignancies.
- Published in:
- BioMed Research International, 2016, v. 2016, p. 1, doi. 10.1155/2016/5218093
- By:
- Publication type:
- Article
Deep Response in Multiple Myeloma: A Critical Review.
- Published in:
- BioMed Research International, 2015, v. 2015, p. 1, doi. 10.1155/2015/832049
- By:
- Publication type:
- Article
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1271807
- By:
- Publication type:
- Article
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
- Published in:
- Nature Medicine, 2015, v. 21, n. 6, p. 572, doi. 10.1038/nm.3867
- By:
- Publication type:
- Article
Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
- Published in:
- Scientific Reports, 2017, p. 45681, doi. 10.1038/srep45681
- By:
- Publication type:
- Article
Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORγt, decreases murine spontaneous intestinal tumorigenesis.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 1, p. 13, doi. 10.1007/s00262-015-1769-2
- By:
- Publication type:
- Article
Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-11680-1
- By:
- Publication type:
- Article
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3189, doi. 10.3390/cancers13133189
- By:
- Publication type:
- Article
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with Bortezomib in Waldenström's macroglobulinemia.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 152, doi. 10.3816/CLML.2011.n.036
- By:
- Publication type:
- Article
P-099: Perturbation of CDK7 and super-enhancer driven transcriptional programs synergistically halts multiple myeloma cell proliferation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S93, doi. 10.1016/S2152-2650(21)02233-3
- By:
- Publication type:
- Article
P-046: B cell transcriptional coactivator POU2AF1 (BOB-1) modulates the protein synthesis and offers a potential vulnerability in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S63, doi. 10.1016/S2152-2650(21)02180-7
- By:
- Publication type:
- Article
P-003: Improving NK cell function in Multiple Myeloma with NKTR-255, a novel polymer-conjugated human IL-15.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S40, doi. 10.1016/S2152-2650(21)02137-6
- By:
- Publication type:
- Article
OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S28, doi. 10.1016/S2152-2650(21)02117-0
- By:
- Publication type:
- Article
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S21, doi. 10.1016/S2152-2650(21)02107-8
- By:
- Publication type:
- Article
OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S6, doi. 10.1016/S2152-2650(21)02083-8
- By:
- Publication type:
- Article
Modulation of NK, T, & B cell sub-populations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e167, doi. 10.1016/j.clml.2019.09.279
- By:
- Publication type:
- Article
Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e162, doi. 10.1016/j.clml.2019.09.270
- By:
- Publication type:
- Article
HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in Myeloma with Potential Impact on Cell Growth and Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e127, doi. 10.1016/j.clml.2019.09.211
- By:
- Publication type:
- Article
CDK4/6 Inhibition Suppresses Myeloma Cell Growth and Viability via Perturbation of E2F Proliferative Program.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e126, doi. 10.1016/j.clml.2019.09.209
- By:
- Publication type:
- Article
YWHAE/14-3-3ε expression impacts the proteasome load contributing to proteasome inhibitor sensitivity in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e111, doi. 10.1016/j.clml.2019.09.184
- By:
- Publication type:
- Article
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e107, doi. 10.1016/j.clml.2019.09.176
- By:
- Publication type:
- Article
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e98, doi. 10.1016/j.clml.2019.09.160
- By:
- Publication type:
- Article
Impact of Chromosome 6q Deletions in Multiple Myeloma and Waldenström's Macroglobulinemia by Next Generation RNA Sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.059
- By:
- Publication type:
- Article
Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e12, doi. 10.1016/j.clml.2019.09.017
- By:
- Publication type:
- Article
A First In-Depth Analysis of Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e13, doi. 10.1016/j.clml.2019.09.018
- By:
- Publication type:
- Article
Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e8, doi. 10.1016/j.clml.2019.09.011
- By:
- Publication type:
- Article
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Non-overlapping Promoter and Super-enhancer Driven Processes Support Myeloma Cell Growth and Survival via Distinct Regulatory Axes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e1, doi. 10.1016/j.clml.2017.03.002
- By:
- Publication type:
- Article
Splicing fator SRSF1 is dsregulated in Multiple Myeloma With Functional and Clinical Significance.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e34, doi. 10.1016/j.clml.2017.03.058
- By:
- Publication type:
- Article
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 12, p. 1, doi. 10.1038/s41408-022-00759-6
- By:
- Publication type:
- Article
Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling.
- Published in:
- Science Translational Medicine, 2012, v. 4, n. 148, p. 1, doi. 10.1126/scitranslmed.3003808
- By:
- Publication type:
- Article
Genomic patterns of progression in smoldering multiple myeloma.
- Published in:
- Nature Communications, 2018, v. 9, p. 1, doi. 10.1038/s41467-018-05058-y
- By:
- Publication type:
- Article
Widespread intronic polyadenylation diversifies immune cell transcriptomes.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04112-z
- By:
- Publication type:
- Article
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-01593-2
- By:
- Publication type:
- Article
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 4, p. 438, doi. 10.1111/j.1365-2141.2011.08864.x
- By:
- Publication type:
- Article
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
- Published in:
- British Journal of Haematology, 2010, v. 149, n. 4, p. 537, doi. 10.1111/j.1365-2141.2010.08127.x
- By:
- Publication type:
- Article
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2006, v. 134, n. 1, p. 37, doi. 10.1111/j.1365-2141.2006.06122.x
- By:
- Publication type:
- Article
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
- Published in:
- Experimental Hematology & Oncology, 2022, v. 11, n. 1, p. 1, doi. 10.1186/s40164-022-00305-x
- By:
- Publication type:
- Article
Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-47793-5
- By:
- Publication type:
- Article
Mechanism of action of immunomodulatory agents in multiple myeloma.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Mechanism of action of immunomodulatory agents in multiple myeloma.
- Published in:
- Medical Oncology, 2010, v. 27, p. 7, doi. 10.1007/s12032-010-9527-y
- By:
- Publication type:
- Article
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-21177-5
- By:
- Publication type:
- Article